Travere Therapeutics To Present 11 Abstracts, Including A Late-Breaking Poster At American Society Of Nephrology Kidney Week 2025 In Houston, TX November 6-9 Highlights Including Data Duplex Study Showing More Filspari-Treated Patients Achieved Proteinuria Below 0.7 G/g Compared With Irbesartan, Indicating Reduced Kidney Failure Risk In FSGS

Author: Benzinga Newsdesk | October 17, 2025 08:09am

Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney failure risk in FSGS

Data presentations highlight biomarker and cardiovascular safety data from SPARTAN Study of FILSPARI in patients with IgAN

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present 11 abstracts, including a late-breaking poster, at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 6-9.

In focal segmental glomerulosclerosis (FSGS), the Company will present:

• A late-breaking analysis from the DUPLEX Study demonstrating that patients treated with FILSPARI® (sparsentan) were more likely to reach proteinuria levels under 0.7 g/g when compared with the maximum labeled dose of irbesartan, and achievement of this threshold correlated with reduced risk of kidney failure irrespective of treatment arm.
• An analysis evaluating the relationship between the magnitude of proteinuria reduction at two years with FILSPARI compared to the maximum labeled dose of irbesartan and long-term kidney outcomes in a subset of DUPLEX aligned participants in the UK National Registry of Rare Kidney Diseases (RaDaR).
• Data showing that FILSPARI-treated children and FILSPARI-treated individuals with COL4A3-5 mutations achieved rapid and sustained reductions in proteinuria compared with the maximum labeled dose of irbesartan in the DUPLEX Study.

Presentations in IgA nephropathy (IgAN) will include:

• New data from SPARTAN demonstrating that among RASI-naïve patients, FILSPARI induced anti-inflammatory and anti-fibrotic effects, regardless of disease severity, as well as favorable effects on cardiovascular risk factors.
• Real-world data reinforcing FILSPARI's ability to consistently lower proteinuria and preserve kidney function.
• Two new analyses from PROTECT showing that, irrespective of time from diagnosis or severity of disease based on kidney biopsy, FILSPARI demonstrated consistent, superior and sustained proteinuria reduction compared to maximum dose irbesartan.

"We look forward to presenting new clinical and real-world data further reinforcing FILSPARI as a foundational treatment for people living with IgA nephropathy and as a potential treatment for FSGS," said Jula Inrig, M.D., chief medical officer of Travere Therapeutics. "Analyses from the DUPLEX Study in FSGS consistently show that FILSPARI achieves clinically meaningful reductions in proteinuria across the FSGS population, including children and genetically mutated forms of the disease. These data support FILSPARI's potential to preserve kidney function and are in alignment with findings from the PARASOL Project, which examined proteinuria as a key predictor of long-term outcomes in FSGS. In IgAN, biomarker data from the SPARTAN Study highlight FILSPARI's potential disease-modifying effect, underscoring its position as foundational therapy and highlighting the importance of early intervention."

 

Posted In: TVTX